[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-ovarian\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-ovarian":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":5},"100449245","registry-platform-ovarian-and-endometrial-cancer-100449245",false,"NCT05129969","Registry Platform Ovarian and Endometrial Cancer","SMARAGD - Clinical Research Platform on Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancer Treatment and Outcomes","SMARAGD","Inclusion Criteria:\n\n* Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):\n\n  * patients with FIGO stage IIb-IV OC who are starting systemic treatment or\n  * patients with recurrent\u002Frelapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent\u002Frelapsed disease.\n* Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.\n* Signed and dated informed consent (IC):\n\n  * Patients participating in PRO module: IC before first therapy cycle\n  * Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* newly diagnosed early-stage OC (FIGO stage I-IIa)\n* Low grade mOC OR\n* Early-stage EC (FIGO stage I-II)","FEMALE","18 Years",{"count":20,"type":21},1975,"ESTIMATED","3 Years","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with advanced or metastatic ovarian cancer (OC) or advanced or metastatic endometrial cancer (EC) in Germany.",[26,27,28,29,30,31,32],"Ovarian Cancer","Endometrial Cancer","Ovary Neoplasm","Endometrial Neoplasms","Carcinoma, Ovarian","Carcinoma","Neoplasm, Ovarian",[34,35,36,37,38,39],"Registry","Health service research","Epidemiology","Germany","Palliative treatment","Palliative care","RECRUITING","2026-01-26",{"date":43,"type":44},"2026-01-28","ACTUAL",{"date":46,"type":44},"2021-11-25",{"date":48,"type":21},"2030-12",{"name":50,"class":51},"iOMEDICO AG","INDUSTRY"]